ISRG
T3Intuitive Surgical, Inc.
Humanoid '25: Humanoid & Service Robot OEMsHumanoid '25: Learned Memory & Interfacing
OverviewIntuitive Surgical, Inc. (ISRG) develops robotic systems like da Vinci for minimally invasive surgery and Ion for lung biopsies, empowering medical professional
Intuitive Surgical, Inc. (ISRG) develops robotic systems like da Vinci for minimally invasive surgery and Ion for lung biopsies, empowering medical professionals globally. The company also provides instruments, training, and services, with recurring revenue accounting for 86% of its total. Intuitive sells to hospitals and care teams, focusing on advanced digital and AI capabilities to improve patient outcomes and surgical efficiency.
- What They Do (Plain English & Analogies)
- Intuitive Surgical is like a high-tech assistant for surgeons. They create advanced robotic systems that help doctors perform complex operations through tiny cuts, making surgery less invasive for patients. Imagine a surgeon sitting at a console, using precise hand controls to guide robotic arms and tiny instruments inside a patient's body, all while watching a magnified 3D view. Their main product, the da Vinci system, is used for many types of surgeries. They also have a system called Ion for lung biopsies, which helps doctors find and diagnose lung cancer early. Beyond the robots themselves, they provide all the specialized tools, training for doctors, and ongoing support to make sure these systems work perfectly and help patients recover faster.
- Very Brief History
- Intuitive Surgical, Inc. was established in 1995 and is headquartered in Sunnyvale, California. The research leading to the da Vinci Surgical System began in the late 1980s at SRI International. The company began marketing the da Vinci system in Europe in 1999 and received FDA approval for general laparoscopic surgery in the U0.S. in 2000. Since then, it has expanded its product portfolio and global presence, becoming a leader in robotic-assisted surgery.
- "Street Stereotype"
- Intuitive Surgical is generally perceived as the established market leader and innovator in robotic-assisted surgery, known for its premium da Vinci systems and strong ecosystem. Investors often view it as a high-growth medical technology company with a significant competitive moat, driven by continuous innovation, expanding procedure adoption, and a large installed base. There's also a focus on its ability to maintain its leadership amidst increasing competition and expand into new clinical areas and geographies.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Intuitive Surgical's customers are primarily hospitals and medical professionals globally. These include large hospital systems, academic medical centers, and smaller surgical facilities. While specific client names are not disclosed in the transcript, examples of potential clients based on their industry presence would include major healthcare providers such as HCA Healthcare, Kaiser Permanente, Mayo Clinic, and other large integrated delivery networks (IDNs) worldwide.
- New Customers / Segments They'Re Targeting
- The company is actively targeting new customer segments and expanding the use of its platforms. This includes driving broader adoption of da Vinci systems in general surgery and gynecology beyond traditional urology procedures, particularly outside the U.S.. They are also expanding the use of their Single Port (SP) platform into new procedures like non-IDE nipple sparing mastectomy and thoracic and colorectal procedures with the new SP stapler. For the Ion platform, they are focused on helping physicians improve lung cancer patient survival through earlier identification of malignancy and streamlining the time from detection to diagnosis with rapid on-site tissue evaluation (ROSE) technology and endobronchial ultrasound integration.
- Supply Chain And Sourcing Geographies
- Intuitive Surgical has made multi-year investments in its supply chain and manufacturing to build industrial scale and optimize production. The company's manufacturing operations are located in Sunnyvale, California (headquarters), Peachtree Corners, Georgia (producing portions of da Vinci XI and X systems), and Mexicali, Mexico (manufacturing over 90% of instruments and accessories for da Vinci Xi and Si systems). The company is also opening new manufacturing locations across Europe. While specific component sourcing geographies are not detailed, the mention of tariffs and efforts to reduce product costs suggests a global supply chain.
- Sales Geographies And Expansion Plans
- Intuitive Surgical currently sells its products directly in the U.S., Western Europe, and Asia Pacific, and indirectly through distributors in other regions. Specific countries mentioned for strong performance include India, Canada, the U.K., Korea, Taiwan, Italy, and Germany. The company has a joint venture in China, IntuFosun, for that market. They are actively working to expand access and drive deeper adoption in countries outside the U.S. with the addition of the XiR system to their portfolio and their overall ecosystem of technologies, training, and services. They also plan to move the SP stapler into measured launch in Korea and Europe in Q2 2026.
- How Key Themes May Help/Hurt
- Intuitive Surgical, as a leader in advanced robotics, is well-positioned to benefit from the broader 'Humanoid '25: Humanoid & Service Robot OEMs' theme. The advancements in AI, particularly Vision-Language-Action (VLA) models and simulation environments like NVIDIA's Isaac Sim, can significantly enhance Intuitive's own digital and AI roadmap, leading to improved decision support, augmented dexterity, and future automation in surgical procedures. Intuitive's extensive physical telemetry dataset and expertise in bimanual coordination and haptic feedback are valuable assets that could contribute to and benefit from the overall progress in embodied AI and robotics. However, the theme's emphasis on rapidly declining unit production costs for humanoids could create a perception of lower cost expectations across the robotics industry, potentially putting pressure on Intuitive's premium pricing model, especially in cost-sensitive international markets. Geopolitical risks impacting robotics supply chains could also affect Intuitive's manufacturing and component sourcing.
3 Main Long-Term Bull Details
- Global Expansion and Procedure Adoption: Intuitive is experiencing broad-based adoption across its da Vinci and Ion platforms, with significant growth in procedures globally, particularly in general surgery and gynecology outside of urology. The increasing percentage of OUS procedures (38% of total da Vinci volume, up from 25% a decade ago) indicates a strong runway for international growth, supported by investments in organizational capabilities, clinical trials, and market access efforts.
- Continuous Innovation and Digital Ecosystem: The company's commitment to innovation, exemplified by the da Vinci 5 system with its Force Feedback instrumentation and advanced data capture capabilities, drives higher utilization and improved outcomes. Ongoing investments in its digital ecosystem, including My Intuitive+ and Intuitive Telepresence, are foundational to its long-term digital and AI roadmap, promising future advancements in telesurgery, decision support, and augmented dexterity.
- Expanding Clinical Evidence and New Indications: Clinical publications continue to reinforce the value of Intuitive's platforms, such as the Mayo Clinic study demonstrating Ion's role in earlier identification of lung cancer malignancy. The company is actively pursuing new product and procedure launches, securing new geographic clearances, and developing technologies like ROSE and endobronchial ultrasound integration, which expand its addressable market and reinforce clinical differentiation.
3 Main Long-Term Bear Details
- Geopolitical and Market Challenges in Key Regions: Ongoing challenges in China, including low tender activity, domestic competition, and policy-driven pricing pressure, as well as lower system placements and cautious outlook in Japan despite recent policy developments, pose headwinds to international growth. Macroeconomic impacts and shifting governmental priorities in parts of Europe also present capital pressure.
- Competitive Intensity and Pricing Pressure: While Intuitive maintains a strong market position, increasing competition from established medical device giants and specialized robotics companies, particularly in soft-tissue robotics, could lead to pricing pressure and impact market share. The need to offer refurbished systems in cost-sensitive markets also reflects this competitive dynamic.
- Impact of Pharmaceutical Products and External Factors: The growth in GLP-1 usage continues to impact da Vinci bariatrics procedures in the U.S., leading to a decline. The company also remains cautious about the potential impact of changes to ACA premium subsidies and patient behavior in the U.S., as well as higher input costs from oil and memory prices.
- Competitors And Differentiation
- Intuitive Surgical faces competition from diversified medical device companies and specialized technology firms. Key competitors include Medtronic (with its Hugo RAS system and Mazor robots for spine surgery), Johnson & Johnson (developing the Ottava system), Stryker (dominant in orthopedic robotics with Mako), CMR Surgical (Versius), Asensus Surgical (Senhance), Zimmer Biomet (ROSA systems), Smith+Nephew (CORI), PROCEPT BioRobotics, Moon Surgical, and Vicarious Surgical. Intuitive differentiates itself through its extensive installed base, demonstrated clinical outcomes, the reliability of its systems, and a comprehensive ecosystem of technologies, training, and services. They emphasize the overall value of their robotic programs to customers, focusing on improved patient outcomes, increased efficiency, and a shift from open to minimally invasive procedures. The da Vinci 5 system, with its advanced features like Force Feedback instrumentation, also provides a competitive edge.
- Recent Performance & What The Market'S Focused On
- Intuitive Surgical reported a solid start to 2026, with Q1 revenue increasing 23% to $2.77 billion and total procedure growth of 17% (16% for da Vinci, 39% for Ion). Non-GAAP operating margin was strong at 39%. The company placed 431 da Vinci systems (including 232 da Vinci 5 systems) and 52 Ion systems. U.S. da Vinci utilization increased 4%, driven by da Vinci 5 systems. The company raised its full-year 2026 da Vinci procedure growth forecast to 13.5% to 15.5% and updated its non-GAAP gross profit margin estimate to 67.5% to 68.5%. The market is focused on the continued adoption and utilization of da Vinci 5, the acceleration of the SP platform, the progress of its digital and AI roadmap, and how the company navigates competitive pressures and macroeconomic challenges in key international markets.
- Revenue Segments And Estimated Mix
- Instruments & Accessories — Mix: ~61.4%; Source: Q1 2026 transcript; Trend: Grew 23% to $1.7 billion
- Systems — Mix: ~23.5%; Source: Q1 2026 transcript; Trend: Grew 24% to $651 million
- Services — Mix: ~15.7%; Source: Q1 2026 transcript; Trend: Grew 19% to $434 million
- Recurring Revenue (overall) — Mix: ~86% of total revenue; Source: Q1 2026 transcript; Trend: Grew 23% to $2.4 billion
- Product Brands
- da Vinci Surgical System
- Ion endoluminal system
- da Vinci 5
- da Vinci Xi
- da Vinci XiR
- SP system
- My Intuitive+
- Intuitive Telepresence
- Force Feedback instruments
- Mega SutureCut Needle Driver
- SP stapler
- SP vessel sealer
Bull / Bear DetailsIntuitive Surgical maintains its leadership in robotic-assisted surgery, driven by robust da Vinci and Ion procedure growth and expanding global adoption. Strat
Thesis
Intuitive Surgical maintains its leadership in robotic-assisted surgery, driven by robust da Vinci and Ion procedure growth and expanding global adoption. Strategic investments in the da Vinci 5, SP platform, and a comprehensive AI/digital roadmap, leveraging unique surgical data and force feedback, position ISRG for innovation-led revenue growth and enhanced patient outcomes. Despite international market challenges, the company's differentiated technology and expanding ecosystem make the bull case compelling as of 2026-07-03.
Bull case
Intuitive Surgical is demonstrating strong and accelerating procedure growth across its platforms, with Q1 2026 seeing a 17% increase in total procedures, including 16% for da Vinci and 68% for SP. The da Vinci 5 system is a key driver, exhibiting 11% higher utilization than Xi, and the company raised its full-year da Vinci procedure growth forecast to 13.5%-15.5%, signaling robust demand and market penetration.
The company continues to drive innovation and expand its product ecosystem. The da Vinci 5 with Force Feedback instruments received additional FDA 510(k) clearances, supporting broader availability through 2026. Significant investments in AI and digital capabilities, leveraging unique surgical data and force feedback, are foundational for future advancements like augmented dexterity and automation, enhancing surgical precision and outcomes.
Strategic international expansion and market access efforts are yielding positive results, with OUS procedures now representing 38% of total da Vinci volume, up from 25% a decade ago. Despite regional challenges, recent favorable policy developments in Japan, including new reimbursements for 7 procedures, and the addition of XiR to the portfolio, enhance global competitiveness and drive deeper adoption.
Bear case
Intuitive faces persistent international market headwinds, particularly in China, where low tender activity, domestic competition, and policy-driven pricing pressures continue, with clarity on new charge codes not expected until 2027. Japan also presents short-term caution due to the financial position of public hospitals and fewer system placements in 2025, despite recent policy changes.
Competitive pressures are intensifying globally, requiring Intuitive to emphasize the overall value of its robotic programs beyond just the system price. While its tiered portfolio, including da Vinci 5, XiR, and refurbished Xi systems, offers competitive advantages, new entrants and cost-sensitive markets could impact market share and pricing power in the long term.
Macroeconomic factors and specific market shifts pose risks, including the negative impact of GLP-1s on U.S. da Vinci bariatrics procedures, which declined approximately 10%. Higher oil and memory prices are expected to unfavorably impact gross margins in the remainder of 2026, and the potential effects of expiring ACA premium subsidies remain a concern.
Bull / Bear Case
- Bear Case
- Intuitive faces persistent international market headwinds, particularly in China, where low tender activity, domestic competition, and policy-driven pricing pressures continue, with clarity on new charge codes not expected until 2027. Japan also presents short-term caution due to the financial position of public hospitals and fewer system placements in 2025, despite recent policy changes. Competitive pressures are intensifying globally, requiring Intuitive to emphasize the overall value of its robotic programs beyond just the system price. Macroeconomic factors and specific market shifts pose risks, including the negative impact of GLP-1s on U.S. da Vinci bariatrics procedures, which declined approximately 10%. Higher oil and memory prices are expected to unfavorably impact gross margins in the remainder of 2026.
- Bull Case
- Intuitive Surgical is demonstrating strong and accelerating procedure growth across its platforms, with Q1 2026 seeing a 17% increase in total procedures, including 16% for da Vinci and 68% for SP. The company raised its full-year da Vinci procedure growth forecast to 13.5%-15.5%, signaling robust demand and market penetration. The da Vinci 5 system is a key driver, exhibiting 11% higher utilization than Xi, and continuous innovation in AI and digital capabilities, leveraging unique surgical data and force feedback, positions ISRG for future advancements. Strategic international expansion is yielding positive results, with OUS procedures now representing 38% of total da Vinci volume, supported by favorable policy developments in Japan and a tiered product portfolio enhancing global competitiveness.
- More Compelling & Why
- Bull. While ISRG's P/E ratio of approximately 48-51x remains elevated compared to the medical equipment industry average (25-26x), its current valuation is below its own historical 3-year and 5-year averages (around 70x). The strongest argument for the bull case is the sustained "innovation-led revenue growth," where Q1 2026 revenue growth of 23% significantly outpaced total procedure growth of 17%. This indicates the company is successfully extracting more value per procedure through new products and its digital ecosystem. My view would flip to bear if procedure growth significantly decelerated below the updated 13.5%-15.5% forecast, or if competitive pressures led to substantial pricing erosion impacting gross margins.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| SP Platform Procedure Growth and New Product Launches (Stapler, Vessel Sealer) | Strong growth in the Single Port (SP) platform and successful launches of new instruments like the stapler and planned vessel sealer indicate effective expansion into new procedure types and markets, diversifying revenue and expanding the total addressable market. | The SP platform's year-over-year procedure growth rate, adoption rates of the SP stapler (especially in the U.S., Korea, and Europe), and updates on the planned SP vessel sealer launch. | Sustained SP procedure growth above 60% and successful broad launch of the stapler (e.g., high usage in relevant cases) are bullish signals. Delays in new product launches or a deceleration of SP procedure growth are bearish signals. | Intuitive Surgical's quarterly earnings reports and conference calls (next expected Q2 2026 earnings call, typically in July 2026); company press releases. | Industry news releases on new surgical device launches; medical conference presentations detailing SP usage and outcomes. | S&P Global Market Intelligence: Surgical device market share data; KeyBanc Capital Markets: MedTech survey data on new product adoption. |
| Full Year 2026 da Vinci Procedure Growth Rate | Procedure growth directly drives Intuitive Surgical's recurring instrument and accessory revenue, which accounts for 86% of total revenue, indicating strong market adoption and system utilization. | The reported full year 2026 da Vinci procedure growth rate in subsequent earnings calls. | Growth within or above the updated forecast range of 13.5% to 15.5% is a bullish signal. Growth below this range is a bearish signal. | Intuitive Surgical's quarterly earnings reports and conference calls (next expected Q2 2026 earnings call, typically in July 2026). | Industry reports on surgical robot procedure volumes from medical associations or government health agencies (if available regionally). | S&P Global Market Intelligence: Healthcare procedure volume data; AlphaSense: Transcript analysis for procedure mentions. |
| International Market Access and Reimbursement Policy Developments (Japan, China) | Favorable reimbursement policies and improved market access are crucial for driving adoption and revenue growth in international markets, which represent a significant long-term growth opportunity for Intuitive Surgical. | The impact of Japan's new policies (incremental reimbursement for high-volume programs and 7 new reimbursed procedures effective June 2026) on Q2 and subsequent quarters' procedure volumes. Progress and clarity on new charge codes and reimbursement policies in China (expected in 2027). | Positive commentary on Japan's procedure growth in the Q2 2026 earnings call is a bullish signal. Further delays or negative developments in China's policy discussions, with clarity not expected until 2027, are bearish signals. | Intuitive Surgical's quarterly earnings reports and conference calls (next expected Q2 2026 earnings call, typically in July 2026); Japanese Ministry of Health, Labor and Welfare (MHLW) announcements; Chinese government policy updates. | Government health ministry websites for Japan and China; industry news outlets covering medical device regulations in these regions. | GlobalData: Healthcare policy tracking; BMI Research: Country-specific healthcare market reports. |
| Advancements and Adoption of AI/Digital Capabilities (ROSE, EBUS, Force Feedback) | Investments in AI and digital capabilities enhance the value proposition of Intuitive's platforms, potentially improving patient outcomes, expanding use cases, and strengthening competitive differentiation in the long term. | Updates on the integration and launch timelines for Rapid On-Site Tissue Evaluation (ROSE) technology and endobronchial ultrasound (EBUS) for the Ion platform. Steady adoption rates of Force Feedback instrumentation through 2026 and beyond. Specific examples of new AI-enabled features being deployed. | Concrete timelines for ROSE/EBUS launch (though not expected in 2026) and strong, consistent adoption of Force Feedback instruments are bullish signals. Delays in these initiatives or a lack of clear progress on AI-enabled features are bearish signals. | Intuitive Surgical's quarterly earnings reports and conference calls (next expected Q2 2026 earnings call, typically in July 2026); company press releases; presentations at medical and robotics conferences. | Google Scholar: Publications citing Intuitive's AI/robotics research; industry forums (e.g., r/robotics) for discussions on new features and capabilities. | CB Insights: AI in healthcare innovation tracking; Gartner: Robotics and AI market reports. |
| da Vinci 5 System Utilization and Installed Base Penetration | Higher utilization of da Vinci 5 systems drives increased instrument and accessory sales per system, improving recurring revenue and demonstrating the value proposition of the new, more advanced platform. | The percentage of da Vinci 5 systems within the total installed base, da Vinci 5 utilization rates relative to da Vinci Xi, and overall U.S. da Vinci utilization growth. | Continued increase in da Vinci 5's proportion of the installed base and sustained utilization rates that are 11% or more higher than Xi are bullish signals. A slowdown in da Vinci 5 adoption or utilization growth is a bearish signal. | Intuitive Surgical's quarterly earnings reports and conference calls (next expected Q2 2026 earnings call, typically in July 2026). | None directly for specific system utilization rates. | Thinknum: Job postings for 'da Vinci 5 specialist' or 'robotic surgery coordinator' at hospitals; Hospital IQ: Surgical suite utilization data (if available for robotic systems). |
Key Reported Metrics, Reratings Triggers & ResultsInternational expansion is a key strategic priority for Intuitive. This metric reflects the success of their global strategy, diversification beyond the U.S. ma
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| OUS da Vinci Procedure Growth | 19% | International expansion is a key strategic priority for Intuitive. This metric reflects the success of their global strategy, diversification beyond the U.S. market, and ability to navigate regional challenges and secure new reimbursements. | OUS da Vinci Procedure Growth needs to hit 20%+ for Q2 2026. This would demonstrate reacceleration or strong resilience against international headwinds, particularly in China and Japan, and would imply outperformance relative to the company's updated full-year 2026 worldwide da Vinci procedure growth forecast of 13.5%-15.5%. | This metric is crucial as international expansion is a key growth driver and diversification strategy for Intuitive Surgical. Exceeding 20% OUS growth would signal effective navigation of geopolitical challenges and robust demand, validating the long-term bull thesis, expanding the addressable market, and supporting a premium valuation. | ||||
| Total Procedure Growth | 17% | This metric is a primary indicator of the adoption and utilization of Intuitive's da Vinci and Ion platforms, directly impacting recurring revenue and overall business health. Continued strong growth validates market demand and the company's expansion efforts. | Total Procedure Growth of 18% or higher for Q2 2026, accompanied by a raised full-year total procedure growth outlook. This would demonstrate sustained acceleration beyond the 17% reported in Q1 2026 and exceed the company's raised da Vinci-specific guidance of 13.5%-15.5% for the full year. | Exceeding 17% total procedure growth would validate Intuitive's innovation-led strategy, particularly da Vinci 5 and Ion adoption. It signals robust market penetration and utilization, reinforcing the recurring revenue model and strengthening its competitive moat, thereby justifying a premium valuation. | ||||
| Non-GAAP Gross Profit Margin | 67.8% | Gross profit margin indicates the company's operational efficiency and ability to manage product costs, especially with the introduction of new systems like da Vinci 5 and Ion. It directly impacts overall profitability and financial performance. | Intuitive Surgical's Non-GAAP Gross Profit Margin needs to hit above 68.5% for the stock to rerate higher. This would exceed the high end of the company's updated full-year 2026 guidance range of 67.5% to 68.5%. While the current value is 67.8%, and the Q1 2026 gross margin was 66.29%, surpassing the 68.5% mark would demonstrate stronger-than-expected operational efficiency and pricing power, especially considering anticipated headwinds from higher oil and memory prices. Peer performance, such as Boston Scientific's 69.16% gross margin in Q1 2026, suggests there is room for upside. Market sentiment, currently positive with renewed buying ahead of earnings, is looking for continued flawless execution to justify the stock's premium valuation. | Achieving a Non-GAAP Gross Profit Margin above 68.5% is crucial as it would signal exceptional operational efficiency and pricing power, especially amidst expected input cost pressures and tariffs. This performance would validate Intuitive Surgical's premium valuation, reinforce its competitive leadership in robotic-assisted surgery, and demonstrate effective cost management and a favorable product mix, thereby exceeding market expectations for profitability. | ||||
Key QuestionsWill the new reimbursement policies in Japan, effective June 2026, and any potential stabilization in China's tender activity, significantly accelerate Intuitiv
Will the new reimbursement policies in Japan, effective June 2026, and any potential stabilization in China's tender activity, significantly accelerate Intuitive Surgical's international da Vinci procedure growth in Q2 2026, offsetting ongoing regional challenges?
- Question 2
Can the accelerating utilization of da Vinci 5 systems and the broader adoption of Force Feedback instrumentation and the SP stapler drive stronger-than-expected Instruments & Accessories (I&A) revenue per procedure and overall gross margin expansion in Q2 2026?
- Question 3
How effectively will Intuitive Surgical's tiered system portfolio, including the da Vinci 5 and refurbished Xi, allow it to defend against increasing domestic and international competition and maintain market share in cost-sensitive markets over the next quarter?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Global Expansion and Innovation:** Management is focused on the global expansion of its platforms (da Vinci, Ion, SP), digital feature releases, and ecosystem enhancements, including investments in organizational capabilities, clinical trials, research, and market access efforts to drive adoption and secure favorable policies and reimbursements internationally. They highlighted the da Vinci 5's broader clinical use, the steady adoption of Force Feedback instrumentation, and the long-term digital and AI roadmap for telesurgery, decision support, and augmented dexterity. 2. **Procedure Adoption and Market Access:** A key priority is increasing adoption for focused procedures by country through training, commercial activities, and market access efforts. This includes strong growth in general surgery in the U.S. and Europe, expansion beyond urology internationally, and efforts to establish favorable patient charge codes and support other market access activities in challenging markets like China and Japan. 3. **Industrial Scale, Quality, and Innovation for New Disease States:** Management is dedicated to building industrial scale, enhancing product quality, and achieving manufacturing optimization. They are also advancing innovation to reach more patients in current and new disease states, such as the progress with the SP platform (including the new stapler and future vessel sealer) and the Ion platform's goal to improve lung cancer patient survival through rapid on-site tissue evaluation (ROSE) and endobronchial ultrasound integration. | Intuitive Surgical delivered a solid start to 2026, with strong procedure and revenue growth driven by broad-based adoption of its da Vinci, Ion, and SP platforms. The company is actively expanding globally, innovating across its digital and AI ecosystems, and strategically managing competition through a diversified product portfolio and value-based approach. While international markets like China and Japan present ongoing challenges, recent policy developments in Japan are encouraging. Management is confident in its long-term strategy, focusing on the Quintuple Aim. The tone of the call was generally positive and confident, reflecting strong financial results and strategic execution. Management expressed optimism about innovation, global expansion, and the value proposition of their platforms, despite acknowledging some macroeconomic headwinds and competitive pressures in specific international markets. The outlook for 2026 da Vinci procedure growth was even slightly increased. | Total revenue grew 19% in Q4 2025. Worldwide procedures (da Vinci and Ion combined) grew 18% in Q4 2025. da Vinci procedures grew 17% in Q4 2025. Ion procedures grew 44% in Q4 2025. Instruments and Accessories (I&A) revenue grew 17% in Q4 2025. Systems revenue grew 20% in Q4 2025. Service revenue grew 21% in Q4 2025. Recurring revenue grew 20% in Q4 2025. SP procedures grew 87% in FY 2025. | 1. **Digital and Data Road Map / AI & ROSE Acquisition (Travis Steed):** Analysts inquired about Intuitive's digital and data road map, including augmented dexterity, and the big-picture view and timing for biopsy and ROSE acquisition. **Management Response:** Dave Rosa explained their AI approach through the lens of the Quintuple Aim, focusing on layered capabilities from high-quality data to meaningful insights delivered as operational guidance, learning support, and in-surgery assistance (e.g., AI-enabled anatomy identification, camera control). He highlighted Intuitive's differentiation through its installed base and unique data sets. For ROSE and EBUS, he stated they are known technologies with short-term timelines (not this year) that will bring significant differentiated value to lung cancer detection and diagnosis. 2. **Appendectomy Opportunity & Japan Reimbursement / Innovation-led Revenue Growth (Larry Biegelsen):** Analysts asked about the size of the appendectomy opportunity in the U.S. and the incremental opportunity from new procedures in Japan. They also asked about "innovation-led revenue growth." **Management Response:** Jamie Samath noted they haven't sized the appendectomy TAM yet, as they are early in its adoption, but are seeing emerging evidence of improved clinical outcomes with da Vinci. Daniel Connally stated it's too early to size the incremental procedure opportunity in Japan from the 7 new reimbursed procedures (largest being bilateral inguinal hernia repair at ~$1,500/procedure), and that the impact would be modest and take time to develop. Jamie Samath explained "innovation-led revenue growth" as a push-and-pull dynamic: differentiated products allow for accretive pricing and value sharing, while cost-sensitive areas benefit from cost reductions passed to customers, creating a beneficial mix dynamic. 3. **Utilization & Global Competition (Robbie Marcus):** Analysts pressed on the impressive utilization growth (after-hours, da Vinci 5) and its translation to future unit growth, as well as Intuitive's strategy for global competition at different price points, including the use of refurbished Xis. **Management Response:** Jamie Samath acknowledged that utilization growth is difficult to quantify long-term but is strategically aligned with customers to increase robotic throughput. He noted da Vinci 5's structural ability to drive higher utilization than Xi and that utilization growth differentiates them from competitors. Dave Rosa emphasized competing on the overall value of the robotic program (outcomes, reliability, ecosystem of services/training) rather than just robot price. Jamie Samath added that their segmented portfolio, including refurbished Xi systems, provides a competitive advantage by offering tiered features and economics for various customer segments. | Total procedures grew 17%. da Vinci procedures grew 16%. Ion procedures increased 39%. Total revenue increased 23% to $2.77 billion. Recurring revenue was higher by 23% to $2.4 billion. In the U.S., total procedures increased 15%, with da Vinci procedures growing 14% and Ion procedures growing 37%. U.S. da Vinci cholecystectomy and appendectomy procedures combined grew 31%. Total U.S. gynecology procedures grew 10%, with non-hysterectomy benign procedures increasing 19%. da Vinci bariatrics procedures in the U.S. declined approximately 10%. Outside the U.S., total procedures grew 20%, with da Vinci procedures growing 19%. SP platform procedures grew 68%. Total Instruments & Accessories (I&A) revenue grew 23% to $1.7 billion. da Vinci I&A revenue per procedure was approximately $1,880, up from $1,780 last year (approx. 5.6% growth). Systems revenue grew 24% to $651 million. da Vinci leasing revenue increased 28%. Service revenue increased 19% to $434 million. Service revenue per system for da Vinci installed base increased 6%. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Intuitive Surgical is expanding its eligible market through several avenues, including the global expansion of its platforms and ecosystem. OUS procedures now represent 38% of total da Vinci volume, up from 25% a decade ago. The company is well-positioned to expand access and drive deeper adoption internationally with the addition of XiR to its system portfolio. FDA 510(k) clearance was received for additional uses of Force Feedback instruments, with five of six instruments now cleared for 15 uses and the Mega SutureCut Needle Driver for 10 uses, supporting broader availability through 2026 and beyond. The Single Port (SP) platform saw 68% year-over-year procedure growth, driven by expansion in Korea and the U.S., and early adoption in select international markets. U.S. surgeons performed the first non-IDE nipple sparing mastectomy cases, and the single-port stapler moved into broad launch to support deeper penetration in thoracic and colorectal procedures. In the U.S., da Vinci procedures grew 14% year-over-year, led by general surgery, and non-hysterectomy benign gynecology procedures increased by 19%. Outside the U.S., da Vinci procedures grew 19%, with strong results in India, Canada, the U.K., Korea, Taiwan, Italy, and Germany. Japan introduced incremental reimbursement for hospitals exceeding 200 robotic procedures annually and granted reimbursement for 7 new procedures, including bilateral inguinal hernia repair, starting June 2026. The company is also investing in cardiac surgery and sees opportunities for SP to address additional disease states not currently served by multi-port systems, potentially expanding the total addressable market. | Intuitive Surgical faces domestic competition and policy-driven pricing pressure in China, where the environment remains challenging with relatively low tender activity. The company emphasizes that competition is about meeting customer needs at the right price point, focusing on the overall value of a robotic program rather than just the robot's price. Intuitive aims to educate customers globally on the value proposition, including demonstrated clinical output, system reliability, and its ecosystem of services and training. The company's portfolio, including the da Vinci 5, refurbished Xi, and XiR systems, allows for a tiered pricing strategy, which is seen as a competitive advantage to cater to various customer segments and cost sensitivities. Refurbished Xi systems, described as very capable with a full ecosystem, offer attractive economics for cost-sensitive markets. | The broader industry is experiencing mixed dynamics, with ongoing challenges in China and Japan impacting growth rates. In China, low tender activity, domestic competition, and policy-driven pricing pressure persist. Japan's procedure growth is below historical levels due to fewer system placements in 2025, though recent policy changes, including new reimbursement for 7 procedures and incremental financial support for high-volume robotic programs, are encouraging. The U.S. bariatrics procedures continue to be negatively impacted by the growth in GLP-1 pharmaceutical products, declining approximately 10%. The company remains cautious about the potential impact of the expiration of subsidies for enhanced premiums under the ACA, although no significant impact was observed in Q1. Capital pressure in parts of Europe due to macroeconomic factors and shifting governmental priorities is also noted. A Mayo Clinic study highlighted that Ion's use supports earlier identification of malignancy in lung cancer patients, with the potential to improve survival, and demonstrated a significant increase in early-stage primary lung cancer diagnosis. | Intuitive Surgical's long-term digital and AI roadmap includes telesurgery, deeper decision support, and augmented dexterity, with aspects of future automation, all aimed at advancing the Quintuple Aim. The company expects adoption of Force Feedback instrumentation to progress steadily through 2026 and beyond. The SP platform will incorporate much of the da Vinci 5 ecosystem, including current and future digital and AI capabilities, in the midterm. Progress is being made on rapid on-site tissue evaluation (ROSE) technology and endobronchial ultrasound integration for Ion to streamline lung cancer detection and diagnosis. Company priorities for 2026 remain global expansion of platforms, increased adoption for focused procedures, building industrial scale and optimizing manufacturing, and advancing innovation to reach more patients. Discussions are ongoing in China regarding new charge code and reimbursement policies, with clarity not expected until 2027. The company plans to drive innovation-led revenue performance with the SP stapler, planned SP vessel sealer, and growth in AI and digital capabilities, as well as increasing the value of the Ion platform through a staging indication and AI-based ROSE technology. The full-year 2026 da Vinci procedure growth forecast has been increased to a range of 13.5% to 15.5%. Non-GAAP gross profit margin is updated to a range of 67.5% to 68.5% of revenue, and non-GAAP operating expense growth is expected between 11% and 14%. Other income is forecast between $315 million and $335 million, and the non-GAAP income tax rate between 22% and 23%. The company anticipates that AI will contribute to advancing outcomes, reducing variation, improving patient and care team experiences, lowering costs, and increasing access. Future AI applications include AI-enabled anatomy identification and more advanced assistance like camera control. The company is also exploring new disease states for its platforms and sees potential for surgeons to apply da Vinci capabilities in unforeseen areas. Internationally, Intuitive plans to continue localized approaches, potentially going direct in more markets, exploring localized manufacturing, and franchising with distributors in new markets. | Humanoid | Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion. da Vinci 5 utilization continues to exceed that of da Vinci Xi, driving U.S. utilization growth to 4%. OUS procedures now representing 38% of total da Vinci volume, up from 25% a decade ago. SP momentum continued in the quarter with procedures growing 68% year-over-year. We are increasing our forecast and now expect full year da Vinci procedure growth within a range of 13.5% to 15.5%. The long-term opportunity for SP is perhaps a little underestimated. | The lower growth rate relative to prior quarters reflects ongoing challenges in China and Japan. In China, the environment remains largely consistent with recent quarters reflecting relatively low tender activity across the category, domestic competition and policy-driven pricing pressure. da Vinci bariatrics procedures in the U.S. continue to be impacted by the growth in use of GLP-1s and declined approximately 10%. While we are encouraged by these steps [in Japan], we remain cautious in our outlook for the Japanese market in the short term given the financial position of public hospitals in recent periods. We do not expect clarity on the outcome of these matters [China charge codes] until 2027. While Q1 results were not significantly impacted by higher oil and memory prices, we do expect those to have a greater unfavorable impact in the remainder of the year. | Intuitive Surgical added 425 employees during the quarter, with 230 of those related to the acquisition of its distribution business in Italy, Spain, and Portugal. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ISRG_b0b97962 | Q3 | 2026-07-01 | 2026-09-30 | Broad launch of the da Vinci SP stapler in Japan. | This expansion will support broader adoption of the SP platform in a key international market, contributing to SP procedure growth and strengthening Intuitive's competitive position. | Ticker | 2026-07-16 | earnings_transcript |
| ISRG_116c11d7 | time lines are more short term, but they won't be this year | 2027-01-01 | 2027-12-31 | Integration and launch of rapid on-site tissue evaluation (ROSE) and endobronchial ultrasound (EBUS) technologies for the Ion platform. | These integrations are expected to bring significant differentiated value to lung cancer detection and diagnosis, potentially improving patient survival and driving Ion platform adoption and revenue. | Ticker | 2026-04-21 | earnings_transcript |
| ISRG_99871711 | broader availability in Q2 that will increase over the rest of the year. We expect adoption of Force Feedback instrumentation to progress steadily through 2026 and beyond. | 2026-04-01 | 2026-12-31 | Broader availability and steady adoption of Force Feedback instrumentation for da Vinci 5 systems following additional FDA 510(k) clearances. | Increased adoption of these instruments is expected to lead to improved surgical outcomes and drive utilization of da Vinci 5 systems, potentially impacting revenue and competitive differentiation. | Ticker | 2026-04-21 | earnings_transcript |
| ISRG_5c4a97d5 | do not expect clarity on the outcome of these matters until 2027 | 2027-01-01 | 2027-12-31 | Clarity on potential new charge code and reimbursement policies for robotic procedures in China. | Favorable policies could significantly improve procedure growth in China, which is currently challenging due to competitive and pricing pressures, materially impacting future revenue. | Ticker | 2026-04-21 | earnings_transcript |
| ISRG_664833dc | remainder of the year | 2026-04-01 | 2026-12-31 | Potential greater unfavorable impact on gross margin from higher oil and memory prices. | This could negatively impact gross profit margins, despite cost reduction efforts, due to increased input costs and logistics, affecting profitability. | Ticker | 2026-04-21 | earnings_transcript |